scholarly journals Diagnosis and management of secondary-progressive multiple sclerosis: time for change

2019 ◽  
Vol 9 (6) ◽  
Author(s):  
Jiwon Oh ◽  
Katayoun Alikhani ◽  
Tania Bruno ◽  
Virginia Devonshire ◽  
Paul S Giacomini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Care ◽  
Treatment Strategies ◽  
Progressive Multiple Sclerosis ◽  
Management Plan ◽  
Diagnostic Tools ◽  
Interdisciplinary Management ◽  
Diagnosis And Management ◽  
Secondary Progressive ◽  
Novel Treatment Strategies

Identifying the transition of relapsing-remitting multiple sclerosis (MS) to the secondary-progressive MS form remains a clinical challenge due to the gradual nature of the transition, superimposed relapses, the heterogeneous course of disease among patients and the absence of validated biomarkers and diagnostic tools. The uncertainty associated with the transition makes clinical care challenging for both patients and physicians. The emergence of new disease-modifying treatments for progressive MS and the increasing emphasis of nonpharmacological strategies mark a new era in the treatment of progressive MS. This article summarizes challenges in diagnosis and management, discusses novel treatment strategies and highlights the importance of establishing a clear diagnosis and instituting an interdisciplinary management plan in the care of patients with progressive MS.

scholarly journals New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis

2021 ◽  
Vol 13 (1) ◽  
pp. 138-144
Author(s):  
D. S. Kasatkin ◽  
N. V. Khachanova ◽  
V. M. Alifirova ◽  
A. N. Boyko ◽  
K. Z. Bakhtiyarova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Practice ◽  
Early Detection ◽  
Progressive Multiple Sclerosis ◽  
Secondary Progressive Multiple Sclerosis ◽  
Point Of View ◽  
Diagnostic Tools ◽  
Urgent Problem ◽  
Clinical Progression ◽  
Secondary Progressive

The process of neurodegeneration in multiple sclerosis (MS) remains an urgent problem of modern neurology; from the point of view of its therapy, it is especially important to identify this condition during the transition to secondary progression. This paper reflects the opinion of the Council of Leading MS Experts on the early detection of secondary progressive MS and its diagnostic tools, including the use of new online questionnaires. Special attention is paid to the concept of clinical progression verification using the indicator of the confirmed progression of disability and to the prospect for introducing siponimod (Kiendra® ) into clinical practice for the treatment of patients with secondary progressive MS.

scholarly journals Living with secondary progressive multiple sclerosis in Europe: perspectives of multiple stakeholders

2021 ◽  
Vol 11 (1) ◽  
pp. 9-19
Author(s):  
Øivind Torkildsen ◽  
Ralf A Linker ◽  
Jose MM Sesmero ◽  
Simone Fantaccini ◽  
Rainel Sanchez-de la Rosa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Multiple Sclerosis ◽  
Secondary Progressive Multiple Sclerosis ◽  
Diagnostic Tools ◽  
Patient Journey ◽  
Secondary Progressive ◽  
Relapsing Remitting ◽  
Assessment Guidelines ◽  
Research Findings ◽  
Relapsing Remitting Multiple Sclerosis

The transition from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (SPMS) remains a clinical challenge owing to the heterogeneous course of the disease, indistinct disease progression and lack of availability of validated biomarkers and diagnostic tools. This article summarizes the outcomes from an international expert group meeting conducted to validate the preliminary research findings gathered through interviews with primary healthcare stakeholders and pharmaceutical representatives, and to understand the current and future patient journey of SPMS across seven European countries. We highlight the uncertainty in SPMS diagnosis and management and, consequently, the need for uniform assessment guidelines, enhanced awareness and a collaborative effort between the stakeholders associated with SPMS patient care and the pharmaceutical industry.

The pathology of primary progressive multiple sclerosis

2004 ◽  
Vol 10 (3_suppl) ◽  
pp. S23-S30 ◽  
Author(s):  
Claudia Lucchinetti ◽  
Wolfgang Bruck
Keyword(s):  
Multiple Sclerosis ◽  
Axonal Injury ◽  
Treatment Strategies ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Limited Information ◽  
Primary Progressive ◽  
Secondary Progressive ◽  
Relapsing Remitting ◽  
Focal Demyelination

The patho logical hallmark of chronic multiple sclerosis includes focal demyelination, gliosis, inflammation and axonal injury. There is limited information on whether these pathological features differ across the clinical pheno types of the disease (relapsing-remitting, secondary progressive, and primary progressive). This review will focus on the patho logical aspects of PPMS and pathogenic implications. A better understanding of the differences in PPMS pathology and patho genesis will lead to more effective treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document